There are currently 1090 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04756726
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's
Register for Updates
From Opinion to Evidence: Multi-site Evaluation of Custom Dynamic Orthosis Best Practices
NCT06352788
Recruiting
This study is designed to support evidence-based practice and optimal care by evaluating how different configurations of two types of carbon fiber custom dynamic orthoses (CDOs) influences outcomes following traumatic lower extremity injury.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/26/2024
Locations: Mayo Clinic - Motion Analysis Lab, Rochester, Minnesota
Conditions: Foot Injury
Register for Updates
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
NCT04543253
Recruiting
Cushing syndrome (CS) is an endocrine disorder caused by chronic exposure to glucocorticoid (GC) excess. Endogenous CS has an estimated incidence of 0.2 to 5.0 cases per million per year and prevalence of 39 to 79 cases per million in various populations. CS usually affects young women, with a median age at diagnosis of 41.4 with a female-to-male ratio of 3:1. Following a curative surgery for CS, patients develop adrenal insufficiency and require GC replacement postoperatively until the hypothal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cushing Syndrome
Register for Updates
Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients
NCT06015932
Recruiting
This clinical trial tests how well cognitive behavioral cancer stress management (CBCSM) group sessions work to decrease psychological distress in cancer patients. CBCSM teaches patients how to recognize and reduce the impacts of cancer associated stress on the biological, psychological, and social life domains.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Register for Updates
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
NCT06106295
Recruiting
The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Multiple Myeloma
Register for Updates
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
NCT05732103
Recruiting
The goal of this phase 1/2 multicenter, open-label, singe arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS). The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
ALgorithms Adapted From Remote Monitoring
NCT05782140
Recruiting
Through the aid of remote monitoring and early symptom detection, a patient's response to stress and normalization to their individual baseline can better contribute towards algorithms which are predictive of clinical decline.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Surgery
Register for Updates
Voice Analysis for Monitoring Patients With Heart Failure
NCT06566911
Recruiting
This observational study involves ADHF patients at two sites in the United States and Germany. After informed consent and screening assessments, participants will perform daily voice recordings during their hospital stay, from admission until discharge. Alongside voice data, additional clinical information such as left ventricular ejection fraction, NTpro-BNP levels, and ECG-data will be collected for comprehensive analysis. The study's goal is to identify voice-based indicators of heart failure... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Heart Failure
Register for Updates
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
NCT03979508
Recruiting
This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy alone, or in combination with pembrolizumab. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/16/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Fibrocystic Change, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Register for Updates
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Prospective Sinonasal Cancer Multi-institution Study
NCT04755855
Recruiting
This is a multi-institution prospective study of patients with sinonasal malignancies. The goal of this study is to learn more about the course of sinonasal cancer, treatment outcomes, and patient quality of life. In addition, central mutational and genomic analysis of tumor tissue will be evaluated.
Gender:
ALL
Ages:
Between 30 days and 99 years
Trial Updated:
08/14/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Sinonasal Carcinoma
Register for Updates